RUNX1 and myelodysplastic syndrome: Importantly, 3 of the 4 patients with “CMP pattern” MDS whose disease was refractory to venetoclax-based therapy (UPN#8, UPN#9, and UPN#12)carried subclones with STAG2 and/or RUNX1 mutations at the time of clinical trial enrollment (Supplementary Data 2).